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Abstract
Background: In persons without clinical symptom it is difficult to assess an impact of probiotics
regarding its effect on health. We evaluated the functional efficacy of the probiotic Lactobacillus
fermentum ME-3 in healthy volunteers by measuring the influence of two different formulations on
intestinal lactoflora, fecal recovery of the probiotic strain and oxidative stress markers of blood and
urine after 3 weeks consumption.
Methods: Two 3-week healthy volunteer trials were performed. Open placebo controlled (OPC)
study participants (n = 21) consumed either goat milk or by L. fermentum ME-3 fermented goat milk
(daily dose 11.8 log CFU (Colony Forming Units). Double blind randomised placebo controlled
(DBRP) study participants (n = 24) received either capsules with L. fermentum ME-3 (daily of dose
9.2 CFU) or placebo capsules.
The faecal lactoflora composition, faecal ME-3 recovery, effect of the consumption on intestinal
lactoflora, and oxidative stress markers of blood (total antioxidative activity; total antioxidative
status and glutathione red-ox ratio) was measured.
Results: ME-3 was well tolerated and a significant increase in total faecal lactobacilli yet no
predominance of ME-3 was detected in all study groups. Faecal recovery of ME-3 was documented
by molecular methods only in fermented milk group, however the significant improvement of blood
TAA (Total Antioxidative Activity) and TAS (Total Antioxidative Status) indices was seen both in
case of fermented goat milk and capsules", yet glutathione re-ox ratio values decreased only in case
of fermented by ME-3 goat milk.
Conclusion: The functional efficacy of both consumed formulations of an antioxidative probiotic
L. fermentum ME-3 is proved by the increase of the intestinal lactobacilli counts providing putative
defence against enteric infections and by reduction of the oxidative stress indices of blood and urine
of healthy volunteers. In non-diseased host the probiotic health claims can be assessed by
improvement of some measurable laboratory indices of well-established physiological functions of
host, e.g. markers of antioxidative defence system.
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Background
Probiotics are defined as live microbial food supplements,
which beneficially influence human health [1,2]. Widely
accepted probiotics contain different lactic acid producing
bacteria of human origin: bifidobacteria, lactobacilli or
enterococci. Nowadays the concept of functional foods,
incl. probiotic food and dietary supplements implies to
their ability to beneficially influence body functions in
order to improve the state of well-being and health and
reduce the risk of disease [2,3]. The important areas of
human physiology that are relevant to functional food sci-
ence according ILSI (International Life Science Institute)
and FUFOSE (The European Commission Concerted
Action on Functional Food Science in Europe) are besides
others, the modulation of basic metabolic processes and
defence against high-grade oxidative stress [4,5].
Human nutrition is clearly associated with oxidative
metabolism, which beside production of energy is
involved in a number of vital functions of the host. For
example, under physiological conditions the reactive spe-
cies (including peroxyl radicals, nitric oxide radical, super-
oxide anion) figure a crucial role in primary immune
defense of the human body by phagocytic cells against
harmful microorganisms [6,7]. On the other hand, a pro-
longed excess of reactive species is highly damaging for
the host biomolecules and cells, resulting in dysbalance of
the functional antioxidative network of the organism and
leading to substantial escalation of pathological inflam-
mation [8].
By our knowledge, no systematic studies have been per-
formed to approve the functional efficacy of different for-
mulations of probiotic on the antioxidative defence
system of a healthy human. In our previous study Lactoba-
cillus fermentum ME-3 (DSM 14241) [9-11], expressed
strong antimicrobial activity against Gram-positive and
Gram-negative entero- and uropathogens [12,13]. The
cells and cell lysate of L. fermentum ME-3 possessed sub-
stantial antioxidative potency [14]. In an animal experi-
ment ME-3 suppressed the excessive oxidative stress
reaction caused by Salmonella  infection in intestinal
mucosa and thus improved the gut mucosal antioxidative
status [15]. The antioxidative effect of L. fermentum ME-3
on human body oxidative stress markers was confirmed
by our pilot study with fermented goat milk [16].
The aim present study was to evaluate the functional effi-
cacy of the probiotic strain L fermentum ME-3 in the
human gastrointestinal tract (GIT) of healthy volunteers.
The faecal recovery, effect of two different formulations
on total faecal lactoflora and oxidative stress markers of
blood and urine were compared after 3 weeks
consumption.
Methods
Formulations
The efficacy of two different formulations (experimental
fermented goat milk and probiotic capsules) on the
human body oxidative stress markers was evaluated.
Lactobacillus fermentum ME-3, a probiotic strain of healthy
human intestinal origin [17], has been identified by bio-
chemical and molecular methods [9]. The patent applica-
tion has been submitted to the Estonian Patent Agency
(Application No. 0356/01PV) as well as to the Interna-
tional Bureau of World Intellectual Property
Organization (WIPO) (Application No. WO03002131)
[11]. L. fermentum ME-3 was used as freeze-dried powder
in capsulated form and in fermented milk.
Capsules
Gelatine coated capsules were manufactured by the
Tallinn Pharmaceutical Company. The freshly prepared
probiotic capsules contained 9.0 logs CFU of L. fermentum
ME-3 per capsule in addition to 250 mg of saccharose and
microcellulose. Identical placebo capsules contained only
saccharose and microcellulose. All capsules were stored at
+4°C.
Survival of ME-3 in capsule
Survival of ME-3 in capsule was monitored during 12
months at +4°C. The content of one capsule was dis-
solved aseptically in 2 ml of 0.9% NaCl solution. The sus-
pension was vortexed, serially diluted and seeded 0.1 ml
on de Man-Rogosa-Sharpe (MRS) agar medium (OXOID,
U.K.) and incubated 48 hours at 37°C microaerobically
(10% CO2). The number of colonies was counted and the
viable cell count in capsule was calculated.
Experimental fermented milk
Three different lots of experimental fermented goat milk
was prepared for the 3-week trial with healthy volunteers
in order to establish the health effects of ME-3 consump-
tion. The study group was supplied with fresh product
once a week. Experimental fermented milk was prepared
as described previously [16] by combining the probiotic
strain with two supportive lactobacilli cultures L.
plantarum LB-4 and L. buchneri S-15. L. buchneri strain S1-
5 decreased the specific taste of the goat milk. L. plantarum
LB-4 was included as a strong producer of exopolysaccha-
rides, which gives the fermented milk a cream-like consist-
ence and delightful acidity. The goat milk was inoculated
with 2% mixture of Lactobacillus strains and incubated at
37°C for 24 hours. Theproduct, ready to use, was cooled
and stored at 4°C.
Survival of L. fermentum ME-3 in fermented goat milk
To measure the viable cell count of ME-3 in fermented
goat milk, samples were taken at the end of fermentationNutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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(before cooling the product), and after 24 h, 32 h, 48 h
and 7 days from the preparation, when the product was
stored at 4°C. The amount of 0.5 ml of the fermented
milk was serially diluted in saline and plated on MRS agar
medium and incubated for 48 h at 37°C in microaerobic
conditions.
Design of human volunteer trials
Two healthy volunteer (n 45) trials, particularly open pla-
cebo controlled (OPC) study and double blind rand-
omized placebo controlled (DBRP) study were carried on
to evaluate the functional efficacy of L. fermentum ME-3 in
the human body. The inclusion criteria included the wish
to participate, no known health problems, and no medi-
cal conditions requiring drug therapy, no other yogurts or
no special diets. The subjects with a history of GIT disease,
food allergy and acute infection, use of any antimicrobial
agent within the last month or use of any regular concom-
itant medication including antioxidant vitamins and anti-
inflammatory non-steroidal drugs were excluded.
The members of the trial were daily questioned about
their general welfare, intestinal function (general welfare,
gut gas production, stool frequency) and putative adverse
effects. The withdrawal criteria from the trials included
acute infections during the study. Reasons for dropout
were the unwillingness to proceed with the study or relo-
cation to new area. The blood samples (6 ml) from the
antecubital vein, faecal and urine samples were collected
before and at the end of all clinical trials. Participants of
all trials gave informed consent to the study protocols
approved by the Ethical Committee of Tartu University.
Open placebo controlled fermented goat milk trial
The study participants were 5 men and 16 women, mean
age 50 years (range 35–60). During three weeks of the trial
the study group (3 males and 13 females) consumed daily
150 ml fermented goat milk. The daily dose of probiotic
Lactobacillus strain was 11.2 to 11.8 log CFU per person.
The control group (1 male and 4 females) consumed the
same dose of fresh goat milk.
Probiotic capsule trial
A DBRP study (ISRCTN 53164826) was carried out as fol-
lows. The study group consisted of 15 men and 9 women,
mean age 52 years (range 40–60) allocated according to
their wish to participate and randomly divided by an
independent person and computer program for two
groups. The study group members (8 males and 4
females) took three probiotic containing capsules (8.4 log
CFU per capsule) two times daily (the daily dose 9.2 log
CFU) during three weeks. The placebo group (7 males and
5 females) received identical capsules without the probi-
otic strain.
Faecal samples of all participants to assess change in faecal
lactoflora and the persistence of the ingested probiotic
strain were collected before and at the end of trial. Several
laboratory indices of blood and urine were measured
before and after the consumption of ME-3. Here we report
on changes in human body oxidative stress markers as
total antioxidative activity (TAA), total antioxidative sta-
tus (TAS) and glutathione red-ox ratio (GSH/GSSG) from
blood serum.
Microbiological analyses of faeces
The total count of lactobacilli and the count of L. fermen-
tum were evaluated in faecal samples. The faecal samples
were collected at day 0 and 21 in both trials. Samples were
kept at -80°C before analyzed. Serial dilutions (10-2–10-9)
of the weighed faecal samples were prepared with phos-
phate buffer (pH 7.2) and 0.05 ml of aliquots was seeded
onto MRS agar medium [17]. The plates were incubated at
37°C for 4 days microaerobically in 10% CO2 environ-
ment (incubator IG 150, Jouan, France). The catalase neg-
ative colonies were selected on the basis of typical for LAB
colony morphology, cells microscopy and Gram staining.
The count of Lactobacillus species was expressed in log10
colony forming units per gram faeces (log10 CFU/g) and
percentage (relative share) in the total count of lactoba-
cilli. The detection level of lactobacilli was a 3.0 log CFU/
g faeces.
The relative amount of L. fermentum, colonizing the gas-
trointestinal tract of persons in the study groups was
expressed as a proportion of the total count (%), using the
Bioquant program [18]). The program gives output data
for every microorganism as an absolute count (log10 CFU/
g) and their percentage in the total count with its normal
values.
AP-PCR typing
The putative ME-3 isolates were typed by arbitrarily
primed polymerase chain reaction (AP-PCR). Genomic
DNA was extracted from 24 h old cultures, cultivated on
MRS agar microaerobically with the QIAamp DNA Mini
Kit 50 (QIAGEN GmbH., Hilden, Germany) according to
the manufacturers instructions. AP-PCR typing was done
with two primers: ERIC1R (5'-ATGTAAGCTCCT
GGGGATTCAC-3') and ERIC2 (5'-AAGTAAGTGACT-
GGGGTGAGCG -3') (DNA Technology A/S, Aarhus, Den-
mark). A 30 µl volume of reaction mixture consisted of 10
× PCR buffer (Fermentas, Vilnius, Lithuania), 2.5 mM
MgCl2 (Fermentas, Vilnius, Lithuania), 200 µM deoxynu-
cleoside triphosphate mixture (dATP, dGTP, dTTP and
dCTP, Amersham Pharmacia Biotech, Freiburg, Germany)
0, 60 µg of each primer and 2.5 U Taq DNA Polymerase
(Fermentas, Vilnius, Lithuania,) and 5 µl of extracted
DNA according to Matsumiya et al. [19]. The PCR mixtureNutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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was subjected to thermal cycling 35 cycles of denaturation
at 95°C for 1 min, annealing at 35°C for 1 min, and
extension at 74°C for 2 min, with a final extension at
74°C for 5 min with the PTC-200 thermal cycler (Eppen-
dorf AG, Hamburg, Germany). The PCR products were
separated by electrophoresis in a horizontal 2% agarose
gel containing 0.1 µl/ml ethidium bromide in Tris-acetic
acid-EDTA (TAE) buffer (40 mM Tris, 20 mM boric acid, 1
mM EDTA, pH 8.3) (Bio-Rad Laboratories, Hercules,
USA) at constant voltage of 120 V. A 1 kb ladder (GeneR-
uler, Fermentas, Vilnius, Lithuania) was used as a base
pair size marker. The banding patterns of isolates were vis-
ualized with UV light and compared with that of L. fer-
mentum ME-3 strain.
Measurement of human body oxidative stress status
Blood serum was analysed for total antioxidative activity
TAA, total antioxidative status TAS and glutathione red/ox
ratio (oxidized glutathione and reduced glutathione,
GSSG/GSH). TAA of the serum was assessed by the lino-
lenic acid test (LA-test) described previously [16]. This test
evaluates the ability of the sample to inhibit lipid peroxi-
dation. TAS of the serum was measured with a commer-
cially available kit (TAS, Randox Laboratories Ltd.
Ardmore, UK) as described elsewhere [16], water-soluble
vitamin E (Trolox) serving as a standard. This method is
based on the inhibition of the absorbance of the ferrylmy-
oglobin radicals of 2,2'-azinobis-ethylbenzothiazoline 6-
sulfonate (ABTS+) generated by activation of metmy-
oglobin peroxidase with H2O2.
The cellular oxidative stress markers as total glutathione
and oxidized glutathione were measured using the
method of Griffith [20] as described elsewhere [16]. The
glutathione content was calculated on the basis of a stand-
ard curve generated with known concentration of glutath-
ione. Amount of GSH (µg/ml) was calculated as a
difference between the total glutathione and GSSG (total
glutathione – GSSG). The glutathione red/ox ratio was
expressed as GSSG/GSH.
Statistical Analysis
The computer program Sigma Stat for Windows 2.0 (Jan-
del Corporation, USA) was applied. The counts of faecal
lactoflora were compared by using Student's t-test and
Mann-Whitney rank sum test. Changes in oxidative stress
markers of blood sera (TAA, TAS and glutathione red-ox
ratio) were evaluated by Student's t-test, paired t-test and
Mann-Whitney rank sum test. The choice of tests was
made automatically according to the distribution of the
data. Both microbial and biochemical markers were given
as mean and standard deviation.
One-way ANOVA test was performed to compare the
effect of different formulation on TAA, TAS and faecal
lactoflora parameters.
Differences were considered statistically significant if the
value was p < 0.05.
Results
Survival of ME-3 in formulations
In capsule after approximately 1-log drop after one week
from the production of the capsules, the viable count of
the probiotic strain remained stable at the level of 8.4 log
CFU per capsule. Additional results have shown at +4°C
the stability of the freeze-dried capsulated culture at least
17 months from the production.
In fermented goat-milk the cell count of the probiotic
strain varied insignificantly from 9.0 to 9.7 log CFU/ml
from one preparation to the other. The viable count of
ME-3 in the fermented goat milk was found to remain sta-
ble at least during 7 days of storage at 4°C.
Human volunteer trials
No dropouts were registered during volunteer trials, yet
one participant was withdrawn from the probiotic capsule
trial due to acute respiratory viral infection. Besides, no
adverse affects in general welfare or changes in GI func-
tionality were assessed during the trial.
Changes in total LAB count
The consumption of both ME-3 fermented milk and ME-
3 capsule significantly increased the total count of lacto-
bacilli in faeces as compared to the initial levels (Fig. 1).
In opposite, in the group of volunteers consuming non-
fermented goat-milk there was even a decrease in total
LAB counts during the 3-week trial and no changes were
found in capsule placebo group.
Recovery of the probiotic strain
In goat milk group L. fermentum as a species appeared in
fecal samples of all individuals (n = 16) after consump-
tion of fermented goat milk (Table 1). The AP-PCR con-
firmed the recovery of ME-3 in the faeces of all study
group members (Fig. 2). However, in different trials the
administration of ME-3 strain did not lead to the predom-
inance of Lactobacillus fermentum species (Table 1).In the
probiotic capsule trial the strain ME-3 was not detectable
between L. fermentum isolates by AP-PCR.
Antioxidative health effect of ME-3
The positive effect on the blood ox stress markers as TAA
and TAS was seen in the case of both formulations (Fig. 3).
Particularly, the additive increase in goat milk group was
6% and 9% respectively as compared to control group,Nutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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Increase of total fecal counts of lactobacilli in healthy volunteers consuming of ME-3 in fermented goat milk and probiotic  capsule Figure 1
Increase of total fecal counts of lactobacilli in healthy volunteers consuming of ME-3 in fermented goat milk 
and probiotic capsule. 1 – Day 0, 2 – Day 21 Significantly different from pre-treatment values (Student's t-test): * p < 0.05; 
Significantly different from control (Student's t-test): ‡ p = 0.01
Table 1: Changes in fecal recovery of L. fermentum during healthy human volunteer trials
L. fermentum
Groups * Prevalence (%) † Count (log10) ‡Proportion (%)
Day 0 Day 21 Day 0 Day 21 Day 0 Day 21
Goat milk trial, ME-3 (n = 16) 25 (4/16) 100 (16/16) 7.0 ± 0.7 7.3 ± 1.4** 21 13
Control (n = 5) - 20 (1/5) - 3.6 - 28
Capsule trial, ME-3 (n = 11) 16.7(2/12) 33.3 (2/12) 4.3 ± 0.5 5.8 ± 1.6 4 9
Placebo (n = 12) 25 (3/12) 16.7 (2/12) 6.3 ± 2.5 8.0 ± 1.6 11 19
* Percentage of subjects with fecal L. fermentum inside the group
** Significantly different from the pre-treatment values (paired t-test): p < 0.001
† Median value ± SD
‡ Proportion of L. fermentum among fecal LAB
Study group control study group placebo
0
2
4
6
8
10
12
Goat milk trial Probiotic capsule trial
12 1 2 1 212
C
F
U
l
o
g
1
0
*
‡
* *Nutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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Confirmation for the survival of L. fermentum ME-3 in GIT in subjects receiving ME-3 fermented goat milk by AP-PCR in a hor- izontal 2% agarose gel Figure 2
Confirmation for the survival of L. fermentum ME-3 in GIT in subjects receiving ME-3 fermented goat milk by 
AP-PCR in a horizontal 2% agarose gel. a) From the left: M – DNA 1 kb Ladder, Line 1 -L. bervis ATCC 14869, Line 2 – L. 
buchneri ATCC 4005, Line 3 – L. reuteri DSM 20016, Line 4 – L. fermentum ATCC 14931, Line 5 – L. fermentum ME-3 b) From 
the left: M – molecular weight marker, Line 1 ...16 – ME-3 like profiles from feces of goat milk trial study group participants
M 1       2       3        4      5      6        7       8       9      10     11     12     13    14   15    16
M 1        2         3          4        5
a)
b)Nutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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Effect of ME-3 consumption in fermented goat milk and capsules on human blood oxidative stress markers a) TAA (%) and b)  TAS(mmol/l) Figure 3
Effect of ME-3 consumption in fermented goat milk and capsules on human blood oxidative stress markers a) 
TAA (%) and b) TAS(mmol/l). 1 – Day 0, 2 – Day 21 Significantly different from pre-treatment values: *p < 0.05 (paired t-
test); **p ≤ 0.01 (Student's t-test and paired t-test);ME-3 goat milk effect different from the effect of the ME-3 in capsule-form 
(ANOVA): ‡p ≤ 0.001
T
A
A
(
%
)
Study group control study group placebo
30
40
50
60
Goat milk trial Probiotic capsule trial
1 2 1  2  1 2 1  2
‡
* * * * * *
a)
T
A
S
(
m
m
o
l
/
l
)
0
1
2
Goat milk trial Probiotic capsule trial
0.5
1.5
12 1 2 1 21 2
Study group control study group placebo
‡
** * **
b)Nutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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however only 4% for TAA and 2.5% for TAS in probiotic
capsule study group as compared to placebo.
The effect of goat-milk consumption on the TAA and TAS
values was significantlyhigher (p < 0.001) than by the
consumption of the capsulated probiotic (Fig. 3). The
decrease of the glutathione red-ox ratio was significant in
both groups: the study Group (from 0.15 ± 0.01 to 0.11 ±
0.04 µg/ml, p < 0.01) and control (from 0.14 ± 0.03 to
0.11 ± 0.02 µg/ml, p < 0.01) in the goat milk trial. When
the probiotic was consumed in capsulated form, no signif-
icant decrease was noticed in the glutathione red-ox ratio.
Discussion
Our aim was to evaluate the functional efficacy of the anti-
microbial and antioxidative probiotic L. fermentum ME-3
in normal population with variable food intake. First of
all the safety of the L. fermentum strain ME-3 was con-
firmed as no adverse side effects were registered in volun-
teers. Even relatively high (>1011 CFU) doses of consumed
ME-3 had no negative impact on the hosts' general well-
being. Lactobacillus fermentum as species, used in various
food applications, has a well-established history of safe
use and is evaluated as GRAS according to the Food and
Drug Administration of the USA [21].
Second, a clear improvement of laboratory indices of anti-
oxidative defence system of a healthy host was docu-
mented, using both formulations as fermented by L.
fermentum ME-3 goat-milk and probiotic capsules. This
effect was simultaneous with the increase of intestinal
lactoflora of healthy volunteers even without necessity for
faecal recovery of the strain. In the human population,
persons without clinical symptoms have still a quite dif-
ferent health status, including stability, capacity and
potency of antioxidative defence to counteract sufficiently
to oxidative stress-caused adverse effects [7]. If a probiotic
is able to exhibit a positive functionality on oxidative
stress-related indices, it helps both to stabilize and pro-
mote the potency of the whole body antioxidative defence
system in subclinical situations without disease symp-
toms. That in turn may have an impact for lowering the
risk of atherosclerotic damage of blood vessels associated
with several cardiovascular and neurodegenerative dis-
eases [22-24].
In our study of healthy volunteers for validation of the
antioxidative functionality of probiotic, four well-known
oxidative stress markers of blood were chosen [25-27].
The state of the lipid fraction (including also LDL) in the
antioxidative defence system of the blood is evaluated by
TAA. TAS on the other hand reflects more the antioxidativ-
ity of the water-soluble fraction of the human blood.
Among the measured blood sera markers both the TAA
and TAS values were also improved in the two different
study groups. However, there was found a significantly
lower improvement of TAA and TAS values in cases of cap-
sule than fermented goat-milk where the recovery of the
strains was assessed by AP-PCR.
Similarly, the reduction of the glutathione red-ox ratio
was detected after the consumption of fermented by ME-
3 goat-milk but not with the capsule. The crucial non-
enzymatic cellular antioxidant is GSH [28] present in the
millimolar range mainly in the red blood cells, liver, pan-
creas, kidneys, spleen, eyes, lungs and intestinal cells [29].
The oxidized form of glutathione becomes even at low
concentrations toxic, and therefore in the cells the glutath-
ione red-ox ratio is kept as low as possible. In the case of
inflammation this balance is shifted towards the oxidized
form, indicating non-physiological intracellular oxidative
stress.
Thus, our study shows that there is a good association
between the mode of formulation of probiotic and
expression of its functional properties inside the healthy
host. The antioxidative potential of the food supplement
containing ME-3 was excellent, as reisolates of the strain
from capsule expressed significantly higher TAA in com-
parison with the base values of the strain in vitro (data not
shown). Unexpectedly, the shifts in the antioxidativity
markers in blood serum of participants of the probiotic
capsule trial were less pronounced in comparison with
ME-3 fermented goat milk.
Particularly, the explanation for more expressed positive
shifts in oxidative stress markers of volunteers of the fer-
mented goat milk trial could be due to the synergistic
effect of the probiotic and the substrate. Milk is not just a
carrier for the probiotic Lactobacillus strain, but contains
natural "lactogenic" factors like lactose, minerals, vita-
mins and other components that enhance the metabolic
activity of ingested probiotic strain in GIT. Both fer-
mented goat milk and goat milk elevated the values of
TAA and TAS The goat milk contains different biomole-
cules (e.g. casomorphins, lactorphins, casokinins, etc)
having certain antioxidative properties, which can con-
tribute to consumers' plasma antioxidative capacity [30-
36]. This was proved by some antioxidative effect also in
persons consuming non-fermented goat milk. However,
the elevation these indices were remarkably more
expressed in the fermented goat milk group, thus the goat
milk fermentation with L. fermentum ME-3 results in addi-
tive increase of total antioxidativity. Therefore, the provi-
sional FAO regulations [37] suggesting the need for health
claims by specified formulations of probiotic seem to be
of the utmost importance.Nutrition Journal 2005, 4:22 http://www.nutritionj.com/content/4/1/22
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Additionally, in our study with experimental fermented
milk the average daily dose of L. fermentum ME-3 being
11.5 logs CFU was clearly higher than that of capsule
(max 9.5 log CFU). It is possible that the dose excesses the
amount of bacteria necessary for interacting with intesti-
nal mucosa and the unattached lactobacilli are excreted
with faeces. The finding of Saxelin and colleagues con-
firmed that the faecal recovery of the probiotic strain
started from the consumption of more than 9.0 log CFU
daily doses of capsulated LGG [38]. To our surprise, in the
present study the similar dose did not result in faecal
recovery of the strain.
It is possible that the ME-3 strain germinated mainly in
some upper parts of intestinal tract where the
advantageous conditions for survival and metabolic activ-
ity of probiotic lactobacilli were present. Using molecular
tools, Marteau et al. showed that lactobacilli figuring only
7% of faecal microflora performed up to 30% of micro-
bial communities in human colon [39]. If administered in
lower quantities as in case of capsule trial, ME-3 did not
reach the detectable level in faecal samples. Yet, its pres-
ence in gut was proved by the positive antioxidative
health effect in blood but not in urine. Therefore it is
understandable that the higher load of metabolically
active probiotic bacteria in goat-milk resulted also in their
faecal recovery and the highest impact on the oxidative
stress indices.
Moreover, in our study the positive impact of ME-3 con-
sumption on the host lactoflora was proved by the
increase of faecal lactobacilli counts in all participants of
human volunteer studies. In experimental settings the
high counts of intestinal lactobacilli have been shown as
an important defensive factor against enteric infections
[40,41]. Though up to now the period of consumption of
probiotics has not been defined, the 3-week ingestion of
fermented goat-milk and capsule seemed enough for
reaching the aims.
It is important to mention that after consumption of ME-
3, a strain with high antagonistic activity, neither the spe-
cies nor the strain predominated among total lactoflora.
This shows a well-granted microbial balance inside the
gut, which cannot be disturbed by high load of probiotic
bacteria. Apparently, the interconnected advanced metab-
olism of large gut microbiota keeps the proportions of dif-
ferent species quite stable. Some other investigators have
obtained similar results showing the proportional
increase of different microbial populations (bifidobacte-
ria, coliforms) after administration of Lactobacillus sp. pro-
biotic [42,43].
Thus, the functional efficacy of different formulations of
anti-infectious and antioxidative probiotic L. fermentum
ME-3 were proved both by the increase of the lactobacilli
counts providing putative defence against infectious
agents in gut and by reduction of the oxidative stress indi-
ces of blood and urine of healthy volunteers. Further,
studies evaluating the efficacy of ME-3 as adjunct to con-
ventional therapy in patients with atherosclerotic dam-
ages and a high-grade oxidative stress are ongoing.
Conclusion
In non-diseased host, the probiotic health claims can be
assessed by improvement of some measurable laboratory
indices of well-established physiological functions of
organism. In our case, the possibility for augmentation of
the antioxidative defence system by the probiotic L. fer-
mentum ME-3 in normal population can be proposed.
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